AIMS: To provide the first description and quantification of symptom changes during interstitial cystitis/bladder pain syndrome and chronic prostatitis/chronic pelvic pain syndrome symptom exacerbations ("flares"). METHODS: Participants at one site of the Trans-Multidisciplinary Approaches to the study of chronic Pelvic Pain Epidemiology and Phenotyping Study completed two 10-day diaries over the 1-year study follow-up period, one at baseline and one during their first flare (if not at baseline). On each day of the diary, participants reported whether they were currently experiencing a flare, defined as "symptoms that are much worse than usual" for at least 1 day, and their levels of urination-related pain, pelvic pain, urgency, and frequency on a scale of 0-10. Linear mixed models were used to calculate mean changes in symptoms between non-flare and flare days from the same participant. RESULTS: Eighteen of 27 women and 9 of 29 men reported at least one flare during follow-up, for a total of 281 non-flare and 210 flare days. Of these participants, 44.4% reported one flare, 29.6% reported two flares, and 25.9% reported ≥ 3 flares over the combined 20-day diary observation period, with reported flares ranging in duration from 1 day to >2 weeks. During these flares, each of the main symptoms worsened significantly by a mean of at least two points and total symptoms worsened by a mean of 11 points for both sexes (all P ≤ 0.01). CONCLUSIONS: Flares are common and correspond to a global worsening of urologic and pelvic pain symptoms.
AIMS: To provide the first description and quantification of symptom changes during interstitial cystitis/bladder pain syndrome and chronic prostatitis/chronic pelvic pain syndrome symptom exacerbations ("flares"). METHODS:Participants at one site of the Trans-Multidisciplinary Approaches to the study of chronic Pelvic Pain Epidemiology and Phenotyping Study completed two 10-day diaries over the 1-year study follow-up period, one at baseline and one during their first flare (if not at baseline). On each day of the diary, participants reported whether they were currently experiencing a flare, defined as "symptoms that are much worse than usual" for at least 1 day, and their levels of urination-related pain, pelvic pain, urgency, and frequency on a scale of 0-10. Linear mixed models were used to calculate mean changes in symptoms between non-flare and flare days from the same participant. RESULTS: Eighteen of 27 women and 9 of 29 men reported at least one flare during follow-up, for a total of 281 non-flare and 210 flare days. Of these participants, 44.4% reported one flare, 29.6% reported two flares, and 25.9% reported ≥ 3 flares over the combined 20-day diary observation period, with reported flares ranging in duration from 1 day to >2 weeks. During these flares, each of the main symptoms worsened significantly by a mean of at least two points and total symptoms worsened by a mean of 11 points for both sexes (all P ≤ 0.01). CONCLUSIONS: Flares are common and correspond to a global worsening of urologic and pelvic pain symptoms.
Authors: Kathleen Joy Propert; Mary McNaughton-Collins; Benjamin E Leiby; Michael P O'Leary; John W Kusek; Mark S Litwin Journal: J Urol Date: 2006-02 Impact factor: 7.450
Authors: Harris E Foster; Philip M Hanno; J Curtis Nickel; Christopher K Payne; Robert D Mayer; David A Burks; Claire C Yang; Toby C Chai; Karl J Kreder; Kenneth M Peters; Emily S Lukacz; Mary P FitzGerald; Liyi Cen; J Richard Landis; Kathleen J Propert; Wei Yang; John W Kusek; Leroy M Nyberg Journal: J Urol Date: 2010-03-29 Impact factor: 7.450
Authors: J Quentin Clemens; Elizabeth A Calhoun; Mark S Litwin; Mary McNaughton-Collins; John W Kusek; Evelyn M Crowley; J Richard Landis Journal: Urology Date: 2009-10-02 Impact factor: 2.649
Authors: J Quentin Clemens; Chris Mullins; A Lenore Ackerman; Tamara Bavendam; Adrie van Bokhoven; Benjamin M Ellingson; Steven E Harte; Jason J Kutch; H Henry Lai; Katherine T Martucci; Robert Moldwin; Bruce D Naliboff; Michel A Pontari; Siobhan Sutcliffe; J Richard Landis Journal: Nat Rev Urol Date: 2019-03 Impact factor: 14.432
Authors: Siobhan Sutcliffe; Catherine S Bradley; James Quentin Clemens; Aimee S James; Katy S Konkle; Karl J Kreder; Hing Hung Henry Lai; Sean C Mackey; Cody P Ashe-McNalley; Larissa V Rodriguez; Edward Barrell; Xiaoling Hou; Nancy A Robinson; Chris Mullins; Sandra H Berry Journal: Int Urogynecol J Date: 2015-03-20 Impact factor: 2.894
Authors: Siobhan Sutcliffe; Robert Gallop; Hing Hung Henry Lai; Gerald L Andriole; Catherine S Bradley; Gisela Chelimsky; Thomas Chelimsky; James Quentin Clemens; Graham A Colditz; Bradley Erickson; James W Griffith; Jayoung Kim; John N Krieger; Jennifer Labus; Bruce D Naliboff; Larissa V Rodriguez; Suzette E Sutherland; Bayley J Taple; John Richard Landis Journal: BJU Int Date: 2019-05-29 Impact factor: 5.588
Authors: J Curtis Nickel; Alisa Stephens; J Richard Landis; Chris Mullins; Adrie van Bokhoven; M Scott Lucia; Garth D Ehrlich Journal: J Urol Date: 2015-09-26 Impact factor: 7.450
Authors: A Petrikovets; I E Veizi; A Hijaz; S T Mahajan; F Daneshgari; C A T Buffington; P McCabe; T Chelimsky Journal: Urology Date: 2019-01-22 Impact factor: 2.649
Authors: H Henry Lai; Joel Vetter; Joseph Song; Gerald L Andriole; Graham A Colditz; Siobhan Sutcliffe Journal: Urology Date: 2019-01-22 Impact factor: 2.649
Authors: Siobhan Sutcliffe; Graham A Colditz; Melody S Goodman; Ratna Pakpahan; Joel Vetter; Timothy J Ness; Gerald L Andriole; H Henry Lai Journal: BJU Int Date: 2014-08-11 Impact factor: 5.588
Authors: Susan L Calcaterra; Traci E Yamashita; Sung-Joon Min; Angela Keniston; Joseph W Frank; Ingrid A Binswanger Journal: J Gen Intern Med Date: 2016-05 Impact factor: 5.128